StonvexLoading…
StonvexStonvexStonvexCore line items from MED's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $76.04M | $385.79M | $310.69M | $221.28M |
Operating Income | $-3.29M | $-14.21M | $-6.41M | $-2.33M |
Net Income | $-2.12M | $-18.67M | $-553.00K | $2.48M |
EPS (Diluted) | $-0.19 | $-1.70 | $-0.05 | $0.15 |
Total Assets | $252.05M | $247.97M | $268.21M | $269.33M |
Total Liabilities | $54.37M | $49.05M | $53.50M | $53.33M |
Cash & Equivalents | $71.53M | $89.30M | $99.53M | $101.69M |
Free Cash Flow OCF − CapEx | $-836.00K | $1.25M | $7.88M | $-2.87M |
Shares Outstanding | 11.12M | 10.99M | 10.99M | 10.99M |